Vaccinating infants against rotavirus also prevents serious disease in unvaccinated older children and adults, according to a study by the Centers for Disease Control and Prevention (CDC). This helps reduce rotavirus-related hospital costs in these older groups. The results of the study are published in the Journal of Infectious Diseases.
Rotavirus is a major cause of severe diarrhea in infants and young children. Before the vaccine, rotavirus was responsible for 58,000 to 70,000 pediatric hospitalizations each year. Routine rotavirus vaccination of U.S. infants started in 2006 and has been very successful at reducing hospitalizations from severe infections in children under 5.
Study author Ben Lopman, PhD, and colleagues assessed whether the benefits of the rotavirus vaccination program also extended to children older than 5 years, adults, and the elderly who are not eligible for the vaccine. The researchers examined nationally-representative data from 2000 to 2008 to determine if hospital admissions for rotavirus and severe diarrhea declined among unvaccinated children and adults.
Rotavirus-related hospital admissions decreased in all age groupsmost significantly in people 5 to 24 years old who were not eligible for the rotavirus vaccine. The largest reduction was in March, the peak month for rotavirus infection, notes Lopman. Also in March, there were significant reductions in rotavirus admissions in people 25 years and older and admissions for severe diarrhea in the elderly. We speculate that vaccinating infants curtailed rotavirus transmission in the community, resulting in fewer infections across the entire population, says Lopman. About 10,000 hospitalizations of children 5 and older were averted in 2008, amounting to about $40 million in healthcare savings.
Our study showed that the burden of rotavirussevere enough to require hospitalizationin older children and adults is larger than we were previously aware, says Lopman. And by vaccinating infants, we can indirectly prevent this burden of disease, thereby amplifying public health and economic benefits of infant vaccination.
In an accompanying editorial, Roger I. Glass, MD, PhD, director of the Fogarty International Center at the National Institutes of Health, speculated that a similar approach could make a big difference in our ability to prevent deaths and severe disease from rotavirus in the developing world. Each year, 600,000 children die as a result of rotavirus infection in low-income countries, including those where rotavirus occurs year-round. Further research is needed in these settings, Glass concluded, noting the benefits and challenges of introducing such a program in lower-income countries.